Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
Crossref DOI link: https://doi.org/10.1007/s12325-021-01991-5
Published Online: 2022-05-24
Published Print: 2022-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Qing
Deering, Kathleen L. http://orcid.org/0000-0003-1438-444X
Harshaw, Qing
Leslie, Lori A.
Funding for this research was provided by:
Janssen Pharmaceuticals
Text and Data Mining valid from 2022-05-24
Version of Record valid from 2022-05-24
Article History
Received: 3 August 2021
Accepted: 9 November 2021
First Online: 24 May 2022